Actively Recruiting
Study on Predicting Response to PD-1 Immunotherapy Using Mass Tissue Imaging in Advanced Non-Small Cell Lung Cancer
Led by University Hospital, Brest · Updated on 2025-02-06
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced non-small-cell lung cancer NSCLC patients to understand why some respond well to PD-1 immunotherapy while others do not. The study focuses on identifying immune system markers in tumor tissue that predict how patients respond to pembrolizumab treatment and who may experience severe immune-related side effects. This observational study aims to improve treatment strategies by examining the tumor environment in detail. The study involves analyzing tumor samples from patients who received pembrolizumab as their first-line treatment between January 2017 and December 2019. Using a new imaging technology called Hyperion, researchers will examine multiple markers in the same tissue section to identify different cell types and their interactions within the tumor. This detailed analysis seeks to find patterns linked to treatment response and toxicity. Participants tumor samples will be studied retrospectively, meaning the researchers will review existing tissue collected during routine care. The main outcome is to find predictive biomarkers of response to anti-PD-1 therapy within one year. As an observational study, there are no new treatments or procedures for participants, and researchers will focus on analyzing tissue and clinical data to gain insights into the tumor microenvironment and its role in treatment outcomes.
CONDITIONS
Brief Title
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
Research Team
M
Margaux GEIER, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here